- Home
- SRAD vs IDYA Comparison
SRAD vs IDYA Comparison
Compare SRAD & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRAD | IDYA |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.6B |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SRAD | IDYA |
|---|---|---|
| Price | $11.89 | $37.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 15 |
| Target Price | $18.27 | ★ $52.38 |
| AVG Volume (30 Days) | ★ 1.9M | 635.0K |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $218,710,000.00 |
| Revenue This Year | $17.76 | N/A |
| Revenue Next Year | $11.98 | $193.45 |
| P/E Ratio | $49.48 | ★ N/A |
| Revenue Growth | N/A | ★ 3024.43 |
| 52 Week Low | $11.51 | $26.05 |
| 52 Week High | $27.85 | $42.68 |
Technical Indicators
Market Signals| Indicator | SRAD | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 36.74 | 51.24 |
| Support Level | N/A | $36.13 |
| Resistance Level | $13.80 | $40.29 |
| Average True Range (ATR) | 0.62 | 1.47 |
| MACD | -0.13 | -0.05 |
| Stochastic Oscillator | 4.63 | 64.17 |
Price Performance
Historical ComparisonAbout SRAD Sportradar Group AG
Sportradar Group AG is a technology platform enabling next-generation engagement in sports, and a provider of B2B solutions to the sports betting industry. It generates revenue through two primary sources: subscription-based revenue and revenue sharing. Geographically, it operates in North America, Africa, AsiaPac & Middle East, Europe, and LATAM & Caribbean.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.